Olema nominates OP-3136, KAT6 inhibitor for breast cancer; IND submission targeted by end of 2024

Olema Pharmaceuticals, Inc.

OP-3136 is an orally bioavailable, potent KAT6A/B-selective inhibitor for ER+ breast cancer.
Preclinical data show dose-dependent tumor regression alone and synergy with CDK4/6 or palazestrant.
IND-enabling studies initiated; goal to file IND with FDA by end of 2024.
Aurigene receives $5M milestone payment upon initiation of IND-enabling studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.